{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T12:19:06Z","timestamp":1703074746683},"reference-count":39,"publisher":"Consilium Medicum","issue":"11","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>HCV infection treatment regimens are viewed from positions of HCV life cycle and replication, effects of NS3\/4A protease inhibitors and NS5A\/NS5B inhibitors on HCV strain replication. Evolution of HCV treatment regimens from its discovery to modern DAA agents had led to substantial progress although drug resistance poses a new issue to be addressed.<\/jats:p>","DOI":"10.26442\/00403660.2019.11.000307","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T15:59:34Z","timestamp":1593446374000},"page":"86-89","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of chronic viral hepatitis C with direct acting antiviral agent: review"],"prefix":"10.26442","volume":"91","author":[{"given":"V A","family":"Malov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E A","family":"Ubeeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I P","family":"Ubeeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S M","family":"Nikolaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K T","family":"Umbetova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"ref1","unstructured":"\u041a\u043b\u0438\u043c\u043e\u0432\u0430 \u0415.\u0410. \u0413\u0435\u043f\u0430\u0442\u0438\u0442 \u0421. \u0412 \u043a\u043d.: \u0418\u043d\u0444\u0435\u043a\u0446\u0438\u043e\u043d\u043d\u044b\u0435 \u0431\u043e\u043b\u0435\u0437\u043d\u0438: \u043d\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u043e\u0435 \u0440\u0443\u043a\u043e\u0432\u043e\u0434\u0441\u0442\u0432\u043e. \u041f\u043e\u0434 \u0440\u0435\u0434. \u042e\u0449\u0443\u043a\u0430 \u041d.\u0414., \u0412\u0435\u043d\u0433\u0435\u0440\u043e\u0432\u0430 \u042e.\u042f. \u041c.: \u0413\u042d\u041e\u0422\u0410\u0420-\u041c\u0435\u0434\u0438\u0430, 2018:688-702."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.20953\/1729-2018-3-37-45"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jh"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01820.x"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Qureshi H, Bile K.M, Jooma R, Alam S.E, Afridi H.U. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J. 2010;16(Suppl):S15-S23.","DOI":"10.26719\/2010.16.Supp.15"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis616"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Manns M.P, Buti M, Gane E, Pawlotsky J.M, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. doi: 10.1038\/ nrdp.2017.6","DOI":"10.1038\/nrdp.2017.6"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30045-6"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2436"},{"key":"ref11","unstructured":"\u0420\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u0432\u0437\u0440\u043e\u0441\u043b\u044b\u0445 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0433\u0435\u043f\u0430\u0442\u0438\u0442\u043e\u043c \u0421. \u042e\u0449\u0443\u043a \u041d.\u0414. \u0438 \u0434\u0440. \u041c.:\u0413\u042d\u041e\u0422\u0410\u0420-\u041c\u0435\u0434\u0438\u0430, 2017."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Stanaway J.D, Flaxman A.D, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad L.J, Assadi R, Bhala N, Cowie B, Forouzanfour M.H, Groeger J, Hanafiah K.M, Jacobsen K.H, James S.L, Mac Lachlan J, Malekzadeh R, Martin N.K, Mokdad A.A, Mokdad A.H, Murray C.J.L, Plass D, Rana S, Rein D.B, Richardus J.H, Sanabria J, Saylan M, Shahraz S, So S, Vlassov V.V, Weiderpass E, Wiersma S.T, Younis M, Yu C, E.l Sayed Zaki M, Cooke G.S. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-8. doi: 10.1016\/ S0140-6736(16)30579-7","DOI":"10.1016\/S0140-6736(16)30579-7"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Reau N, Kwo P.Y, Rhee S, Brown R.S. Jr, Agarwal K, Angus P, Gane E, Kao J.H, Mantry P.S, Mutimer D, Reddy K.R, Tran T.T, Hu Y.B, Gulati A, Krishnan P, Dumas E.O, Porcalla A, Shulman N.S, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir\/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68(4):1298-307. doi: 10.1002\/ hep.30046","DOI":"10.1002\/hep.30046"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3248"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Lohmann V, K\u00f6rner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285(5424):110-3.","DOI":"10.1126\/science.285.5424.110"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette J.C, Opolon P. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum. 1999;42(10): 2204-12.","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Takehara T, Hayashi N, Mita E, Hagiwara H, Ueda K, Katayama K, Kasahara A, Fusamoto H, Kamada T. Detection of the minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: Implications for hepatitis C virus replication in infected tissue. Hepatology. 1992;15(3):387-90.","DOI":"10.1002\/hep.1840150305"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-346"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1000"},{"key":"ref23","unstructured":"Multi-Center, Randomized, Open-Label Study of G\/P +\/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects. https:\/\/clinicaltrials.gov\/ct2\/show\/ NCT03092375"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00815-16"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Forns X, Lee S.S, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson D.R, Yu Y, Krishnan P, Lin C.W, Kort J.J, Mensa F.J. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single - arm, open - label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062-8. doi: 10.1016\/ S1473-3099(17)30496-6","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Foster G.R, Wang S, Asatryan A, Gane E, Feld J.J, Asselah T, Bourli\u00e8re M, Ruane P.J, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang W.L, Stedman C.A, Flamm S, Kwo P, Dore G.J, Sepulveda-Arzola G, Roberts S.K, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas H.E, Bruck R, Fuster F, Paik S.W, Felizarta F, Kort J, Fu B, Liu R, Ng T.I, Pilot-Matias T, Lin C.W, Trinh R, Mensa F.J. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354-69. doi: 10.1056\/ NEJMoa1702417","DOI":"10.1056\/NEJMoa1702417"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"ref28","unstructured":"Wilson E, et al. Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience (RESOLVE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02745535"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i2.92"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70074-4"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1233813"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Asselah T, Kowdley K.V, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry P.S, Hezode C, Marinho R.T, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng T.I, Krishnan P, Lin C.W, Mensa F.J. Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417-26. doi: 10.101 6\/j.cgh.2017.09.027","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i40.8910"},{"key":"ref36","unstructured":"\u0410\u043f\u0440\u043e\u0441\u0438\u043d\u0430 \u0417.\u0413. \u0425\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u043a\u0442\u0438\u0432\u043d\u044b\u0439 \u0433\u0435\u043f\u0430\u0442\u0438\u0442 \u043a\u0430\u043a \u0441\u0438\u0441\u0442\u0435\u043c\u043d\u043e\u0435 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u0435. \u041c.: \u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0430, 1981."},{"key":"ref37","unstructured":"Chung R.T, et al. Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant. https:\/\/clinicaltrials.gov\/ct2\/show\/ NCT03623568"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.011"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.035"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33713\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T21:14:55Z","timestamp":1634159695000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2019.11.000307","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,15]]}}}